A European project led by IDIBAPS will test a diagnostic genomic test for breast cancer to improve patients’ quality of life
Sharing Progress in Cancer Care (SPCC) is proud to be Associated Partner of the European DEFINITIVE Project, led by CLÍNIC-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).
The DEFINITIVE Project will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that use of genomic test HER2DX® improves quality of life in patients with early-stage HER2+ breast cancer while also maintaining drug efficacy.
Its goal is to demonstrate the clinical utility of minimal invasive diagnostic HER2DX® by improving quality of life and reducing toxicities and direct and indirect costs, as well as maintaining the efficacy endpoints and survival outcomes compared to patients treated without the test.
The project will receive 8 million euros from Horizon Europe under the HORIZON-MISS-2023-CANCER round of funding, as part of the European Commission’s key funding program for research and innovation. By bringing “specific solutions to some of our greatest challenges”, EU Mission Cancer aims to improve, by 2030, the lives of over 3 million individuals affected by cancer, along with their families, through prevention and cure, enabling them to live longer and better.
This landmark study will be pivotal in bolstering the clinical validations already acquired for HER2DX®. The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe. As a collaborating partner in this study, REVEAL GENOMICS® is committed to generating robust evidence designed to influence and evolve standard clinical practices.
Dr. Tomás Pascual, medical oncologist, researcher at Hospital Clínic/IDIBAPS, SOLTI executive board member, and Principal Investigator in the DEFINITIVE clinical trial, expressed his optimism about the trial’s potential impact, “This trial represents a significant opportunity to enhance patients’ quality of life without compromising the efficacy of the treatment. It employs a non-invasive diagnostic tool, HER2DX®, to achieve this goal. We are immensely grateful to all our partners and the multidisciplinary team participating in this trial. Their collaboration has been instrumental in developing this project and will be crucial to its successful delivery.”
Dr. Patricia Villagrasa, CEO and co-founder of REVEAL GENOMICS®, stresses that “at REVEAL GENOMICS, we believe in pushing the boundaries of precision medicine. The start of the DEFINITIVE study for HER2DX® is a crucial step in our journey to reshape how oncology treatments are approached and administered globally.”
Read more here.